Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway

doi: 10.2147/COPD.S580964

Figure Lengend Snippet: Airway remodeling and LAMC2 upregulation are observed in both COPD patients and mouse models. ( A ) Representative Masson’s trichrome-stained lung sections from non-smokers (n=5), smokers without COPD (n=5), and COPD patients (n=5). Scale bar: 250μm. ( B ) Quantitative staining of Masson content in non-smoker (n=5), smoker (n=5), and COPD (n=5). ( C ) Representative Masson’s trichrome staining of lung sections from air-exposed control mice (n=5) and COPD model mice (n=5). Scale bar: 100μm. ( D ) Quantitative staining of Masson content in air-control (n=5) and COPD model mice (n=5). ( E ) LAMC2 expression levels in airway epithelial cells from non-smokers (n=12), smokers (n=12), and COPD patients (n=6) based on the GSE5058 dataset. ( F ) Representative airway LAMC2 immunohistochemical staining on lung sections of non-smoker (n=5), smoker (n=5), and COPD (n=5). Scale bar: 50μm. ( G ) Quantitative staining of LAMC2 intensity on airway epithelium of non-smoker (n=5), smoker (n=5), and COPD (n=5). ( H ) LAMC2 expression levels in lung tissues from air-control (n=30) and COPD model mice (n=34) based on the GSE87292 dataset. ( I ) Western blot and ( J ) quantitative analysis of LAMC2 protein expression in the lung tissue from mice from different groups (n=3 mice/group). ( K ) Representative airway LAMC2 immunohistochemical staining on lung sections of air-control (n=5) and COPD model mice (n=5).Scale bar: 100μm. ( L ) Quantitative staining of LAMC2 intensity on airway epithelium of air-control (n=5) and COPD model mice (n=5). Data presented as the means ± SD. * P < 0.05, ** P < 0.01.

Article Snippet: The membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature and then incubated overnight at 4°C with the following primary antibodies: GAPDH (1:5000; Cell Signaling Technology, Danvers, MA, USA), LAMC2 (1:1000; Proteintech, China), E-Cadherin (1:1000; Cell Signaling Technology), N-Cadherin (1:1000; Cell Signaling Technology), Fibronectin (1:1000; HUABIO, China), AKT (1:1000; Cell Signaling Technology), and phospho-AKT (p-AKT, 1:1000; Cell Signaling Technology).

Techniques: Staining, Control, Expressing, Immunohistochemical staining, Western Blot

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway

doi: 10.2147/COPD.S580964

Figure Lengend Snippet: Knockdown of LAMC2 attenuates airway remodeling and EMT in a COPD model. ( A ) Schematic overview of the animal experimental design and grouping. ( B ) Representative Masson staining on mice lung sections from different groups (n = 5 per group). ( C ) Quantitative staining of Masson content in different groups (n = 5 per group). ( D ) Representative airway Fibronectin immunohistochemical staining and ( E ) quantitative staining of Fibronectin intensity on lung sections of different groups (n = 5 per group). ( F ) Representative airway N-cadherin immunohistochemical staining and ( G ) quantitative staining of N-cadherin intensity on lung sections of different groups (n=5 per group). ( H ) Representative airway E-cadherin immunohistochemical staining and ( I ) quantitative staining of E-cadherin intensity on lung sections of different groups (n=5 per group). ( J – M ) Western blot analysis and quantification of EMT-related proteins (Fibronectin, N-cadherin, and E-cadherin) in lung tissues from the different treatment groups. * P < 0.05, ** P < 0.01, *** P < 0.001. Scale bars: 100μm.

Article Snippet: The membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature and then incubated overnight at 4°C with the following primary antibodies: GAPDH (1:5000; Cell Signaling Technology, Danvers, MA, USA), LAMC2 (1:1000; Proteintech, China), E-Cadherin (1:1000; Cell Signaling Technology), N-Cadherin (1:1000; Cell Signaling Technology), Fibronectin (1:1000; HUABIO, China), AKT (1:1000; Cell Signaling Technology), and phospho-AKT (p-AKT, 1:1000; Cell Signaling Technology).

Techniques: Knockdown, Staining, Immunohistochemical staining, Western Blot

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway

doi: 10.2147/COPD.S580964

Figure Lengend Snippet: LAMC2 expression is upregulated in bronchial epithelial cells following TGF-β1 stimulation. ( A and B ) Volcano plots illustrating DEGs from ( A ) GSE104908 and ( B ) GSE40374 datasets, with corresponding LAMC2 expression levels. Significantly upregulated genes (red) and downregulated genes (blue) are indicated (fold change >1.5, adjusted P < 0.05). ( C ) The mRNA levels of Fibronectin, N-cadherin, E-cadherin, and LAMC2 after treatment with different concentrations of TGF-β1 for 24 hours. ( D ) Western blot and ( E – H ) the relative protein level of Fibronectin, N-cadherin, E-cadherin, and LAMC2 after treatment with different concentrations of TGF-β1 for 24 hours. The data are the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature and then incubated overnight at 4°C with the following primary antibodies: GAPDH (1:5000; Cell Signaling Technology, Danvers, MA, USA), LAMC2 (1:1000; Proteintech, China), E-Cadherin (1:1000; Cell Signaling Technology), N-Cadherin (1:1000; Cell Signaling Technology), Fibronectin (1:1000; HUABIO, China), AKT (1:1000; Cell Signaling Technology), and phospho-AKT (p-AKT, 1:1000; Cell Signaling Technology).

Techniques: Expressing, Western Blot

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway

doi: 10.2147/COPD.S580964

Figure Lengend Snippet: Knockdown of LAMC2 reverses TGF-β1-induced EMT marker expression and inhibits 16HBE cell migration. ( A ) LAMC2 mRNA expression levels following transfection with different siLAMC2 constructs. ( B ) mRNA expression of Fibronectin, N-cadherin, and E-cadherin after siLAMC2 transfection and subsequent TGF-β1 treatment. ( C ) Western blot and ( D – F ) the relative protein level of Fibronectin, N-cadherin, E-cadherin, and LAMC2 after siLAMC2 transfection and TGF-β1 treatment. ( G ) Representative images of wound healing and transwell migration assays under different treatment conditions. Scale bar: 20 μm. ( H ) Quantification of migration rate (%) from wound healing assay and ( I ) Cell migration numbers counted from transwell assays. The data are the mean ± SD. ** P < 0.01, *** P < 0.001.

Article Snippet: The membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature and then incubated overnight at 4°C with the following primary antibodies: GAPDH (1:5000; Cell Signaling Technology, Danvers, MA, USA), LAMC2 (1:1000; Proteintech, China), E-Cadherin (1:1000; Cell Signaling Technology), N-Cadherin (1:1000; Cell Signaling Technology), Fibronectin (1:1000; HUABIO, China), AKT (1:1000; Cell Signaling Technology), and phospho-AKT (p-AKT, 1:1000; Cell Signaling Technology).

Techniques: Knockdown, Marker, Expressing, Migration, Transfection, Construct, Western Blot, Wound Healing Assay

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway

doi: 10.2147/COPD.S580964

Figure Lengend Snippet: Overexpression of LAMC2 promotes TGF-β1-induced EMT and enhances 16HBE cell migration. ( A ) LAMC2 mRNA expression levels following transfection with LAMC2 plasmid and TGF-β1treatment. ( B ) mRNA expression of Fibronectin, N-cadherin, and E-cadherin after LAMC2 plasmid vector transfection and subsequent TGF-β1 treatment. ( C ) Western blot and ( D – F ) the relative protein level of Fibronectin, N-cadherin, E-cadherin, and LAMC2 after LAMC2 plasmid vector transfection and TGF-β1 treatment. ( G ) Representative images of wound healing and transwell migration assays under different treatment conditions. Scale bar: 20 μm. ( H ) Quantification of migration rate (%) from wound healing assay and ( I ) Cell migration numbers counted from transwell assays. The data are the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature and then incubated overnight at 4°C with the following primary antibodies: GAPDH (1:5000; Cell Signaling Technology, Danvers, MA, USA), LAMC2 (1:1000; Proteintech, China), E-Cadherin (1:1000; Cell Signaling Technology), N-Cadherin (1:1000; Cell Signaling Technology), Fibronectin (1:1000; HUABIO, China), AKT (1:1000; Cell Signaling Technology), and phospho-AKT (p-AKT, 1:1000; Cell Signaling Technology).

Techniques: Over Expression, Migration, Expressing, Transfection, Plasmid Preparation, Western Blot, Wound Healing Assay

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway

doi: 10.2147/COPD.S580964

Figure Lengend Snippet: LAMC2 facilitates EMT in 16HBE cells through activation of the AKT signaling pathway. ( A ) GO enrichment analysis of down-regulated DEGs from RNA-seq data, showing the top three most significantly enriched terms in each category: Biological Process (BP), Cellular Component (CC), and Molecular Function (MF) (adjusted P < 0.05). Terms are ranked by gene count. ( B ) KEGG pathway analysis of down-regulated DEGs. Statistically significant pathways (adjusted P < 0.05) are visualized in a dot plot. ( C ) Western Blot and ( D ) Immunofluorescence detection, and ( E – G ) the relative protein level of AKT and p-AKT after si-NC/LAMC2 transfection and TGF-β1 treatment. ( H ) Western Blot and ( I ) Immunofluorescence detection, and ( J – L ) the relative protein level of AKT and p-AKT after LAMC2 plasmid vector transfection and TGF-β1 treatment. Scale bar: 50 μm. The data are the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature and then incubated overnight at 4°C with the following primary antibodies: GAPDH (1:5000; Cell Signaling Technology, Danvers, MA, USA), LAMC2 (1:1000; Proteintech, China), E-Cadherin (1:1000; Cell Signaling Technology), N-Cadherin (1:1000; Cell Signaling Technology), Fibronectin (1:1000; HUABIO, China), AKT (1:1000; Cell Signaling Technology), and phospho-AKT (p-AKT, 1:1000; Cell Signaling Technology).

Techniques: Activation Assay, RNA Sequencing, Western Blot, Immunofluorescence, Transfection, Plasmid Preparation

Journal: Cell

Article Title: Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer

doi: 10.1016/j.cell.2017.10.044

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Monoclonal mouse LAMC2, clone CL2980, lot #CL2980 , Novus Biologicals , Cat#NBP2-42388.

Techniques: RNAscope, Labeling, Virus, Recombinant, Cloning, Transfection, Plasmid Preparation, Control, Software

Journal: Aging (Albany NY)

Article Title: RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocarcinoma tissues

doi: 10.18632/aging.203589

Figure Lengend Snippet: The differential expression of key genes in different GEO datasets.

Article Snippet: The following primary antibodies were used: RUNX2 (ABclonal, cat. no. A2851), LAMC2 (ABclonal, cat. no. A1869), AKT (Cell signaling Technology, cat. no. #4685), p-AKT (Cell signaling Technology, cat. no. #4060), p-c-Raf (Cell signaling Technology, cat. no. #9421), p-MEK1/2 (Cell signaling Technology, cat. no. #9154), p-ERK1/2 (Cell signaling Technology, cat. no. #4370), p-p90RSK (Cell signaling Technology, cat. no. #9346), p-MSK1 (Cell signaling Technology, cat. no. #9595), and β-Actin (Abmart, cat. no. P30002).

Techniques: Expressing

Journal: Aging (Albany NY)

Article Title: RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocarcinoma tissues

doi: 10.18632/aging.203589

Figure Lengend Snippet: The differential expression of candidate miRNAs in different GEO datasets.

Article Snippet: The following primary antibodies were used: RUNX2 (ABclonal, cat. no. A2851), LAMC2 (ABclonal, cat. no. A1869), AKT (Cell signaling Technology, cat. no. #4685), p-AKT (Cell signaling Technology, cat. no. #4060), p-c-Raf (Cell signaling Technology, cat. no. #9421), p-MEK1/2 (Cell signaling Technology, cat. no. #9154), p-ERK1/2 (Cell signaling Technology, cat. no. #4370), p-p90RSK (Cell signaling Technology, cat. no. #9346), p-MSK1 (Cell signaling Technology, cat. no. #9595), and β-Actin (Abmart, cat. no. P30002).

Techniques: Expressing

Journal: Aging (Albany NY)

Article Title: RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocarcinoma tissues

doi: 10.18632/aging.203589

Figure Lengend Snippet: Expression, ROC and survival analysis of key genes. ( A – C ) Differential expression of key genes (RUNX2, LAMC2 and FXBO32) in various tumor and non-tumor tissues. ( D ) Differential expression of key genes in PC patients and normal controls. ( E ) ROC curve of key genes in GSE62165, GSE15471 and GSE32688. ( F ) Survival analysis of key genes in TCGA PAAD cohort.

Article Snippet: The following primary antibodies were used: RUNX2 (ABclonal, cat. no. A2851), LAMC2 (ABclonal, cat. no. A1869), AKT (Cell signaling Technology, cat. no. #4685), p-AKT (Cell signaling Technology, cat. no. #4060), p-c-Raf (Cell signaling Technology, cat. no. #9421), p-MEK1/2 (Cell signaling Technology, cat. no. #9154), p-ERK1/2 (Cell signaling Technology, cat. no. #4370), p-p90RSK (Cell signaling Technology, cat. no. #9346), p-MSK1 (Cell signaling Technology, cat. no. #9595), and β-Actin (Abmart, cat. no. P30002).

Techniques: Expressing

Journal: Aging (Albany NY)

Article Title: RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocarcinoma tissues

doi: 10.18632/aging.203589

Figure Lengend Snippet: Verification of key genes. ( A ) RUNX2, LAMC2 and FXBO32 expression levels (Log2FoldChange value) in GSE14245, GSE74629, GSE49641, GSE49515 and GSE15932. ( B ) Representative immunohistochemistry staining of RUNX2 and LAMC2 in pancreatic ductal adenocarcinoma (PC tissue) and control pancreatic tissue (Normal tissue) in Human Protein Atlas (HPA). Scales bars represent 200 μm. ( C ) Western blot analysis for RUNX2 and LAMC2 expression proteins in 16 paired samples from PC patients.

Article Snippet: The following primary antibodies were used: RUNX2 (ABclonal, cat. no. A2851), LAMC2 (ABclonal, cat. no. A1869), AKT (Cell signaling Technology, cat. no. #4685), p-AKT (Cell signaling Technology, cat. no. #4060), p-c-Raf (Cell signaling Technology, cat. no. #9421), p-MEK1/2 (Cell signaling Technology, cat. no. #9154), p-ERK1/2 (Cell signaling Technology, cat. no. #4370), p-p90RSK (Cell signaling Technology, cat. no. #9346), p-MSK1 (Cell signaling Technology, cat. no. #9595), and β-Actin (Abmart, cat. no. P30002).

Techniques: Expressing, Immunohistochemistry, Staining, Western Blot

Journal: Aging (Albany NY)

Article Title: RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocarcinoma tissues

doi: 10.18632/aging.203589

Figure Lengend Snippet: The clinical application value of RUNX2 and LAMC2 expression. ( A ) Expression levels of RUNX2 and LAMC2 in pancreatic cancer (PC) patients of different clinical stages. ( B ) Expression levels of RUNX2 and LAMC2 in different sex groups of PC patients. ( C ) Expression levels of RUNX2 and LAMC2 in different age groups of PC patients. ( D ) Expression levels of RUNX2 and LAMC2 in different tumor subtypes of PC patients. ( E ) Expression levels of RUNX2 and LAMC2in different tumor status groups of PC patients. ( F ) Survival analysis of combined RUNX2 and LAMC2 in TCGA PAAD cohort.

Article Snippet: The following primary antibodies were used: RUNX2 (ABclonal, cat. no. A2851), LAMC2 (ABclonal, cat. no. A1869), AKT (Cell signaling Technology, cat. no. #4685), p-AKT (Cell signaling Technology, cat. no. #4060), p-c-Raf (Cell signaling Technology, cat. no. #9421), p-MEK1/2 (Cell signaling Technology, cat. no. #9154), p-ERK1/2 (Cell signaling Technology, cat. no. #4370), p-p90RSK (Cell signaling Technology, cat. no. #9346), p-MSK1 (Cell signaling Technology, cat. no. #9595), and β-Actin (Abmart, cat. no. P30002).

Techniques: Expressing

Journal: Aging (Albany NY)

Article Title: RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocarcinoma tissues

doi: 10.18632/aging.203589

Figure Lengend Snippet: LAMC2 and RUNX2 participate in PC cell growth and migration. ( A , B ) ASPC-1 cells were transfected with control shRNA (NC) or two shRNAs of different sequences targeting LAMC2 or RUNX2 for 48 h; cell samples were collected and subjected to western blot analysis. ( C , D ) Cell growth curves of control, LAMC2- and RUNX2-depleted cells were measured by RTCA (Real Time Cellular Analysis). ( E ) Cell migration of control, LAMC2- and RUNX2-depleted cells were plotted by transwell assay.

Article Snippet: The following primary antibodies were used: RUNX2 (ABclonal, cat. no. A2851), LAMC2 (ABclonal, cat. no. A1869), AKT (Cell signaling Technology, cat. no. #4685), p-AKT (Cell signaling Technology, cat. no. #4060), p-c-Raf (Cell signaling Technology, cat. no. #9421), p-MEK1/2 (Cell signaling Technology, cat. no. #9154), p-ERK1/2 (Cell signaling Technology, cat. no. #4370), p-p90RSK (Cell signaling Technology, cat. no. #9346), p-MSK1 (Cell signaling Technology, cat. no. #9595), and β-Actin (Abmart, cat. no. P30002).

Techniques: Migration, Transfection, shRNA, Western Blot, Transwell Assay

Journal: Aging (Albany NY)

Article Title: RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocarcinoma tissues

doi: 10.18632/aging.203589

Figure Lengend Snippet: LAMC2 and RUNX2 regulate PC cell growth and migration through PI3K/AKT and MAPK pathway. ( A , B ) ASPC-1 cells were stably transfected with control shRNA (NC) or two shRNAs of different sequences targeting LAMC2 or RUNX2; cell samples were collected and subjected to Western blot analysis of p-AKT, p-c-Raf, p-MEK1/2, p-ERK1/2, p-P90RSK and p-MSK1. Actin was used as a loading control. The data expressed in right graphs represent the mean ± SEM (*p < 0.05).

Article Snippet: The following primary antibodies were used: RUNX2 (ABclonal, cat. no. A2851), LAMC2 (ABclonal, cat. no. A1869), AKT (Cell signaling Technology, cat. no. #4685), p-AKT (Cell signaling Technology, cat. no. #4060), p-c-Raf (Cell signaling Technology, cat. no. #9421), p-MEK1/2 (Cell signaling Technology, cat. no. #9154), p-ERK1/2 (Cell signaling Technology, cat. no. #4370), p-p90RSK (Cell signaling Technology, cat. no. #9346), p-MSK1 (Cell signaling Technology, cat. no. #9595), and β-Actin (Abmart, cat. no. P30002).

Techniques: Migration, Stable Transfection, Transfection, shRNA, Western Blot

Journal: International Journal of Molecular Sciences

Article Title: miR-212-5p Regulates PM 2.5 -Induced Apoptosis by Targeting LAMC2 and LAMA3

doi: 10.3390/ijms26041761

Figure Lengend Snippet: miR-212-5p negatively regulates LAMC2 and LAMA3: ( A ) miRanda (v3.3a) and TargetScan (v5.0) projected miR-212-5p target genes displayed; ( B ) similarity of rno-miR-212-5p and has-miR-212-5p genes shown; ( C ) schematic representation of LAMC2-3′ UTR and LAMA3-3′ UTR with miR-212-5p target prediction and reporter plasmid construction, where red characters indicate binding sites and ”*” characters indicate mutation sites; ( D ) luciferase activity assessed in 293T cells after co-transfection of LAMC2-WT, LAMC2-MUT, LAMA3-WT, and LAMA3-MUT with miR-212-5p mimics or miR-mimics NC for 48 h; ( E ) LAMC2-mVenus-WT, LAMC2-mVenus-MUT, LAMA3-mVenus-WT, and LAMA3-mVenus-MUT co-transfected with miR-mimics NC or miR-212-5p in 293T cells (scale bar: 300 µm); ( F ) RT-PCR assay for miR-212-5p mimics and miR-212-5p inhibitors on LAMC2 and LAMA3 expression after transfection; ( G ) Western blotting used to identify alterations in the LAMC2 and LAMA3 proteins. The mean ± standard deviation ( n = 3) is used to express the data. ns, no significance; *, p < 0.05; **, p < 0.01; and ***, p < 0.001 indicate significance.

Article Snippet: miR-212-5p mimics in line with negative controls (miR-mimics NC), miR-212-5p inhibitors in line with negative controls (miR-inhibitor NC), and siRNAs for LAMC2 and LAMA3 (siRNA−LAMC2, siRNA−LAMA3) were obtained from GenePharma (Suzhou, China), and details are displayed in .

Techniques: Plasmid Preparation, Binding Assay, Mutagenesis, Luciferase, Activity Assay, Cotransfection, Transfection, Reverse Transcription Polymerase Chain Reaction, Expressing, Western Blot, Standard Deviation

Journal: International Journal of Molecular Sciences

Article Title: miR-212-5p Regulates PM 2.5 -Induced Apoptosis by Targeting LAMC2 and LAMA3

doi: 10.3390/ijms26041761

Figure Lengend Snippet: PM 2.5 -induced changes in LAMC2 and LAMA3 expression: ( A ) LAMC2 and LAMA3 gene expression detected with RT-PCR after PM 2.5 stimulation; ( B ) LAMC2 and LAMA3 protein changes detected with Western blotting; ( C ) silencing efficiency of LAMC2 and LAMA3 after transfection with siRNA−LAMC2 or siRNA−LAMA3 detected with RT-PCR; ( D ) LAMC2 and LAMA3 protein changes detected with Western blotting. The mean ± standard deviation ( n = 3) is used to express the data. ns, no significance; *, p < 0.05; **, p < 0.01; and ***, p < 0.001 indicate significance.

Article Snippet: miR-212-5p mimics in line with negative controls (miR-mimics NC), miR-212-5p inhibitors in line with negative controls (miR-inhibitor NC), and siRNAs for LAMC2 and LAMA3 (siRNA−LAMC2, siRNA−LAMA3) were obtained from GenePharma (Suzhou, China), and details are displayed in .

Techniques: Expressing, Gene Expression, Reverse Transcription Polymerase Chain Reaction, Western Blot, Transfection, Standard Deviation

Journal: International Journal of Molecular Sciences

Article Title: miR-212-5p Regulates PM 2.5 -Induced Apoptosis by Targeting LAMC2 and LAMA3

doi: 10.3390/ijms26041761

Figure Lengend Snippet: LAMC2 and LAMA3 inhibit apoptosis through the PI3K/AKT/NF-κB pathway: ( A ) PM 2.5 -stimulated (180 μg/mL for 24 h) cells transfected with siRNA−LAMC2 or siRNA−LAMA3, and p-IκBα/IκBα and p-p65/p65 protein changes; ( B ) p-AKT/AKT and p-p85/p85 protein changes; ( C ) BCL-2, BAD, and caspase-3 protein changes detected with Western blotting; ( D ) apoptosis rate detected with flow cytometry. The mean ± standard deviation ( n = 3) is used to express the data. ns, no significance; *, p < 0.05; **, p < 0.01; and ***, p < 0.001 indicate significance.

Article Snippet: miR-212-5p mimics in line with negative controls (miR-mimics NC), miR-212-5p inhibitors in line with negative controls (miR-inhibitor NC), and siRNAs for LAMC2 and LAMA3 (siRNA−LAMC2, siRNA−LAMA3) were obtained from GenePharma (Suzhou, China), and details are displayed in .

Techniques: Transfection, Western Blot, Flow Cytometry, Standard Deviation